Return of daily living skills is a practical measure of success in treatment of serious mental illness. In phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, three second-generation antipsychotic medications and perphenazine modestly improved psychosocial functioning but did not differ from each other. Swartz et al. (CME, p. 428) examined changes in scores on the Quality of Life Scale, which evaluates social functioning, interpersonal relationships, vocational functioning, and psychological functioning. Perphenazine, olanzapine, ziprasidone, and risperidone produced similar changes, and results were comparable for clozapine in phase 2E. Swartz et al. suggest that more targeted vocational rehabilitative efforts are needed for schizophrenia. As an example, McGurk et al. (p. 437) improved employment outcomes for patients with schizophrenia by adding a cognitive training program to supported employment. The program included cognitive assessment, computer-based training, and ongoing consultation. Over 2–3 years, patients in the combined program had better employment outcomes than those in supported employment only. The average total number of weeks worked was 5.4 for supported employment only but 27.0 weeks for the combined program. An editorial by Dr. John Lauriello on p. 377 addresses real-world outcomes in schizophrenia.